M617-1613 Screening compound: N-[2-(4-METHYLPIPERIDIN-1-YL)ETHYL]-10-OXO-11-[(PYRIDIN-2-YL)METHYL]-1811-TRIAZATRICYCLO[7.4.0.0{27}]TRIDECA-2468-TETRAENE-5-CARBOXAMIDE

M617-1613 Screening compound: N-[2-(4-METHYLPIPERIDIN-1-YL)ETHYL]-10-OXO-11-[(PYRIDIN-2-YL)METHYL]-1811-TRIAZATRICYCLO[7.4.0.0{27}]TRIDECA-2468-TETRAENE-5-CARBOXAMIDE
M617-1613 Screening compound: N-[2-(4-METHYLPIPERIDIN-1-YL)ETHYL]-10-OXO-11-[(PYRIDIN-2-YL)METHYL]-1811-TRIAZATRICYCLO[7.4.0.0{27}]TRIDECA-2468-TETRAENE-5-CARBOXAMIDE alternative view

Chemical Structure Depiction of ChemDiv screening compound M617-1613
N-[2-(4-METHYLPIPERIDIN-1-YL)ETHYL]-10-OXO-11-[(PYRIDIN-2-YL)METHYL]-1811-TRIAZATRICYCLO[7.4.0.0{27}]TRIDECA-2468-TETRAENE-5-CARBOXAMIDE

Available from 1 mg

Formats:

  • Glass Vials (4ml Glass Vials VWR #97047-678)
  • 96-tube racks (Matrix #4247 96-well 1.4ml sealed with capmats, empty cols 1 & 12, 100uL of 10mM)

Shiptime: 1 week worldwide delivery in most cases

Compound Identifiers

ChemDiv Compound ID

M617-1613

Molecular Formula

C25H30N6O2 (C25 H30 N6 O2)

Compound Name

N-[2-(4-METHYLPIPERIDIN-1-YL)ETHYL]-10-OXO-11-[(PYRIDIN-2-YL)METHYL]-1811-TRIAZATRICYCLO[7.4.0.0{27}]TRIDECA-2468-TETRAENE-5-CARBOXAMIDE

IUPAC name

n/a

SMILES

CC1CCN(CCNC(c(cc2)cc3c2n(CCN(Cc2ncccc2)C2=O)c2n3)=O)CC1

InChI

InChI=1S/C25H30N6O2/c1-18-7-11-29(12-8-18)13-10-27-24(32)19-5-6-22-21(16-19)28-23-25(33)30(14-15-31(22)23)17-20-4-2-3-9-26-20/h2-6,9,16,18H,7-8,10-15,17H2,1H3,(H,27,32)

InChI Key

VRUNLNNNCCZHSS-UHFFFAOYSA-N

MDL Number (MFCD)

MFCD27549213

Chemical and Physical Properties

Saltdata

n/a

Molecular Weight

446.55

Hydrogen Bond Acceptors Count

7.00

Hydrogen Bond Donors Count

1.00

Rotatable Bond Count

7.00

Number of Nitrogen and Oxygen Atoms

8

Partition Coefficient, logP

1.970

Distribution Coefficient, logD

1.090

Water Solubility, LogSw

-2.75

Polar Surface Area

64.663

Acid Dissociation Constant (pKa)

12.54

Base Dissociation Constant (pKb)

8.22

Number of Chiral Centers

0.00

Percent sp3 carbon bonding

44.00

M617-1613 in Drug Discovery

Included in Screening Libraries

300k Representative Compounds Library (Bemis-Murcko Clustering Algorithm) (286253 compounds)

DGK Inhibitors Library (10558 compounds)

Nonpeptide Peptidomimetics PPI Library (18997 compounds)

Protein-Protein Interaction Library (218420 compounds)

SmartTM Library (51161 compounds)

Epigenetics Focused Set (26518 compounds)

Included in 1.7M Stock Database

Therapeutical areas:
  • Cancer
  • Digestive system
  • Hemic and lymphatic
  • Skin
  • Metabolic
  • Immune system
Targets:
  • Kinases
Mechanism of action:
  • PPI modulators
  • PPI modulators
Structure:
  • Mimetics

References: we are preparing a list of scientific research reports with M617-1613 chemical compound. It will be published here after verification.

Frequently Asked Questions

How to purchase chemical compound M617-1613?
Check Price and Availability of M617-1613, then you can add required amount to the Shopping Cart. In the Shopping Cart you can again refine your selection. Once you are sure that it’s exactly what you want you can move forward with the Checkout (to pay online by credit card, or via PayPal), or Request a Quote.
What is the minimum amount of M617-1613 you sell to drug discovery company or institution?
Available from 1 mg in Glass Vials or 96-tube racks.
Delivery options for M617-1613
ChemDiv sends parcels with Express services (UPS, WC).
  • 1–2 days for small orders
  • 2–4 weeks for large selections
Delivery formats for M617-1613
  • 0.5–50 mg of dry powder sample in single glass vials, custom vials
  • DMSO solutions frozen 10μl–250μl@10mM (96 and 384 format)

Custom synthesis of M617-1613 available by request